- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Javed Butler Discusses the Possibility of HFpEF Combination Treatment
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), with empagliflozin and mineralocorticoid receptor antagonists (MRA) showing promise, noted Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Transcript
What are your thoughts on a combination regimen for HFpEF that contains empagliflozin or an SGLT2 inhibitor as the anchor drug?
I completely agree with that mindset. That mindset we had, and we were successful in HFrEF, so nobody questioned what is the drug for HFrEF to give combination therapy. And if you now look at this, we now have data with empagliflozin for EF [ejection fraction] all the way up to 65%. We'll see what happens above 65% soon, but we know that valsartan/sacubitril with median EF of less than 57% showed benefit. If you exclude the Russia/Georgia data from TOPCAT and all the heterogeneity that we saw, MRA seems to be benefiting as well. And now, obviously, we have HFpEF trials going on with MRA.
I would say that the HFpEF treatment, or at least a segment of HFpEF treatment, will start looking very much like HFrEF. But certainly, with EMPEROR-Preserved, empagliflozin all the way up to 65% is pretty much a straightforward answer.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
